NESTOR MICHAEL 4

Accession 0001003642-18-000080

CIK 0001003642other

Filed

May 7, 8:00 PM ET

Accepted

May 8, 4:14 PM ET

Size

26.4 KB

Accession

0001003642-18-000080

Form 4

Period: 2018-05-04

President, Impax Pharm. Div.

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−32,500→ 0 total
Exercise: $27.97Exp: 2021-05-11→ Common Stock (32,500 underlying)
Disposition to Issuer
Restricted Common Stock
2018-05-04−19,728→ 0 total
Disposition to Issuer
Common Stock
2018-05-04−56,796→ 0 total
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−52,000→ 0 total
Exercise: $17.99Exp: 2023-05-15→ Common Stock (52,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−56,232→ 0 total
Exercise: $9.35Exp: 2027-03-02→ Common Stock (56,232 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−32,500→ 0 total
Exercise: $20.30Exp: 2020-05-26→ Common Stock (32,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−52,801→ 0 total
Exercise: $33.27Exp: 2026-02-26→ Common Stock (52,801 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−47,500→ 0 total
Exercise: $40.70Exp: 2025-02-26→ Common Stock (47,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−55,000→ 0 total
Exercise: $25.24Exp: 2024-05-14→ Common Stock (55,000 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−32,500→ 0 total
Exercise: $20.90Exp: 2022-05-23→ Common Stock (32,500 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2018-05-04−16,250→ 0 total
Exercise: $6.55Exp: 2019-05-20→ Common Stock (16,250 underlying)

Footnotes (3)

[F1]Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
[F2]Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Amount represents net amount of shares exchanged after required tax withholding with respect to such vesting.
[F3]Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.

Documents

1 file

Impax Laboratories, LLC

CIK 0001003642

Entity typeother